Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018–22
JAC-Antimicrobial Resistance · 03.09.2024 · 6 (5)
DOI: 10.1093/jacamr/dlae150 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 17.09.2024. Verfasst von Mark G Wise und 6 weiteren Autor:innen. Beteiligte Einrichtung: IHMA, Schaumburg, IL, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme.
Abstract (Originalsprache)
Objectives
To assess the in vitro antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam and comparator agents against clinical isolates of Gram-negative bacilli collected in Israel from 2018 to 2022.
Methods
Six clinical laboratories each collected up to 250 consecutive Gram-negative isolates per year from patients with bloodstream, intra-abdominal, lower respiratory tract and urinary tract infections. MICs were determined by CLSI broth microdilution and interpreted with 2024 EUCAST breakpoints. Acquired β-lactamase gene carriage was investigated for most ceftolozane/tazobactam- and imipenem/relebactam-resistant isolates.
Results
Among the full collection of Enterobacterales (n = 4420), 95.1% were susceptible to ceftolozane/tazobactam, including 95.3% of putative AmpC/ESBL-positive, non-carbapenem-resistant Enterobacterales (CRE) phenotype Escherichia coli and 86.6% of AmpC/ESBL-positive, non-CRE phenotype Klebsiella pneumoniae. Overall, 99.8% of non-Morganellaceae Enterobacterales (n = 3723) were imipenem/relebactam susceptible including 98% of the MDR isolates. Most Pseudomonas aeruginosa isolates (n = 1182) were inhibited by ceftolozane/tazobactam (93.9% susceptible) and imipenem/relebactam (94.7%). Imipenem/relebactam retained activity against ≥78% of cefepime-resistant, ceftazidime-resistant, and piperacillin/tazobactam-resistant P. aeruginosa, while ceftolozane/tazobactam inhibited the greatest percentage of meropenem-resistant P. aeruginosa (67.4%) among comparator β-lactam antimicrobials. Molecular characterization showed the majority of imipenem/relebactam-resistant Enterobacterales harboured a metallo-β-lactamase, while half of the ceftolozane/tazobactam-resistant Enterobacterales carried an acquired ESBL or AmpC. Most of the imipenem/relebactam- and ceftolozane/tazobactam-resistant P. aeruginosa characterized did not possess acquired β-lactamases.
Conclusions
Recent clinical isolates of Enterobacterales and P. aeruginosa collected in Israel were highly susceptible to ceftolozane/tazobactam and imipenem/relebactam.
Autor:innen und Institutionen
- IHMA, Schaumburg, IL, USA.
- MSD, Dubai, United Arab Emirates.
- Merck & Co., Inc., Rahway, NJ, USA.
ORCID-Profile: Mark G Wise
Förderung
- Merck Sharp & Dohme
Zitieren
APA
Wise, M. G., DeRyke, C. A., Alekseeva, I., Siddiqui, F., Young, K., Motyl, M. R., & Sahm, D. F. (2024). Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018–22. JAC-Antimicrobial Resistance, 6(5). https://doi.org/10.1093/jacamr/dlae150
Vancouver
Wise MG, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, et al. Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018–22. JAC-Antimicrobial Resistance. 2024;6(5). doi:10.1093/jacamr/dlae150
BibTeX
@article{Wise2024,
author = {Wise, Mark G and DeRyke, C Andrew and Alekseeva, Irina and Siddiqui, Fakhar and Young, Katherine and Motyl, Mary R and Sahm, Daniel F},
title = {Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018–22},
journal = {JAC-Antimicrobial Resistance},
year = {2024},
volume = {6},
number = {5},
doi = {10.1093/jacamr/dlae150}
}
EUVIMED